- Home
- GENK vs TOVX Comparison
GENK vs TOVX Comparison
Compare GENK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | TOVX |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.3M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GENK | TOVX |
|---|---|---|
| Price | $1.93 | $0.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 8.9M |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | 62.50 | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $0.16 |
| 52 Week High | $5.57 | $1.50 |
Technical Indicators
Market Signals| Indicator | GENK | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 49.42 |
| Support Level | $1.58 | $0.17 |
| Resistance Level | $2.21 | $0.27 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 54.57 | 20.63 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.